VERU Veru Inc
Company Analysis
Latest News
🔴 Veru is trading 6.1% down today amid declines in major indexes and biotech stocks
Veru is trading 6.1% lower at $2.29 amid broader market pressure. - The S&P 500 is down 1.16%, while the Nasdaq is down 2.08%. - Biotech stocks are weaker,...
Oppenheimer Sees Veru at $24 While Shares Languish Near $2 — Can a Single Trial Close That Gap?
Shares of Veru Inc. jumped 10.4% to $2.35 after Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $24 price target — citing confidence...
🟢 Veru is trading 10.37% up today as Oppenheimer reaffirmed Outperform and $24 target
Veru is trading at $2.35, up +10.37%, after Oppenheimer reaffirmed its Outperform rating and $24 price target. - The reaffirmation is a company-specific...
🟢 Veru is trading 5.6% up today after Oppenheimer reaffirmed Outperform, $24 target
Veru is trading 5.6% up at $2.25 after Oppenheimer reaffirmed its Outperform rating and $24 price target. - Investing.com linked the reaffirmation to an...
🟢 Veru is trading 5.5% up in pre-market after Oppenheimer reiterated its Outperform rating
Veru is trading 5.48% up in pre-market at $2.31; Oppenheimer’s reiterated Outperform rating is a plausible company-specific catalyst. - Investing.com reported...
🔴 Veru is trading 5.4% down today amid broader biotech weakness
Veru is trading 5.4% down at $2.28, with biotech-sector weakness a possible context, not a confirmed direct cause. - No clear Veru-specific announcement...
🔴 Veru is trading 6.5% down in pre-market with no clear company catalyst identified
Veru is trading 6.5% lower at $2.37 in pre-market, with no fresh company-specific announcement identified; biotech-sector weakness may also be a factor, but it...
Veru Pivots Sabizabulin Development to Target Drug-Resistant Pancreatic Cancer
Veru Inc. announced a strategic shift in its drug development pipeline for its oral agent, sabizabulin. Based on new positive preclinical data showing efficacy...
🟢 Veru is trading 5.3% up today in pre-market
Veru is trading at $2.78, up 5.30% in pre-market, with no clear catalyst currently identified. - No new company-specific announcement dated September 8, 2026,...
🟢 Veru is trading 6% up in pre-market
Veru is trading 5.95% up at $2.85 in pre-market, with no fresh company-specific announcement identified to clearly explain the move. - Latest major updates...
🟢 Veru is trading 5% up today
Veru is trading 5.14% higher at $2.76, with no clear company-specific catalyst identified for August 31, 2026. - Latest notable updates include the August 10...
🟢 Veru is trading 6% up in pre-market; catalyst remains unclear
Veru is trading 6.29% up at $2.79, with no new company-specific announcement identified for August 31, 2026 and the immediate catalyst unclear. - Latest major...
🟢 Veru is trading 5% up today as XBI gains 2.06%
Veru is trading 5.02% up at $2.72, with biotech-sector momentum the strongest available explanation; no new company-specific announcement was identified on...
🔴 Veru is trading 5.9% down in pre-market with no new catalyst identified
Veru is trading 5.9% down now at $2.54 (-5.93%), with no new company-specific catalyst identified for August 14, 2026. • Veru’s latest major announcement was...
🔴 Veru is trading 5.65% down in pre-market
Veru is trading 5.65% down now at $2.61, with no confirmed catalyst identified for the August 11 pre-market decline. - Veru gained 18.88% to $2.77 on August...
🔴 Veru is trading 5% down in after-hours trading after Q3 loss and effectively zero revenue
Veru is trading 5.05% down at $2.63 after fiscal third-quarter results showed a $0.30-per-share loss and effectively zero revenue. - The loss modestly beat...
Veru Beats Q3 Estimates and Overfills Its Obesity Trial — But Can a $36 Million Biotech Survive Long Enough to Prove Its Drug Works?
Shares of Veru Inc. surged 15% to $2.68 Monday morning after the company posted fiscal third-quarter results that narrowed losses faster than Wall Street...
🟢 Veru is trading 15% up today after narrower-than-expected Q3 EPS loss
Veru is trading 15.02% up now at $2.68 after fiscal Q3 2026 results showed a narrower-than-expected $0.30 EPS loss and continued progress in its obesity...
Veru Inc's third quarter 2026 EPS loss of $0.30 beat estimates as enobosarm trial enrollment exceeded targets
Veru reported a narrower-than-anticipated net loss for its third quarter of fiscal 2026, although revenue was effectively non-existent as the company continues...
Veru Inc Q3 2026 Earnings Preview: What Analysts Expect on August 10, 2026
Veru is expected to report a consensus revenue of $3.15 million and an EPS loss of -$0.34 for the fiscal quarter ending June 30, 2026, while the current stock...